Hereditary spherocytosis, recessive (SPTA1/alpha-spectrin) OMIM 270970

In Hereditary spherocytosis, recessive (SPTA1, OMIM 270970), the master switch sits on the ↓ DOWN branch (cited role × mechanism, below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: — Honest hold (no matched agent). Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.3753, γ 1.2253, spinodal 0.5220). The corrective direction is an interpretation of the model (a code output whose sign follows from the cited lesion role and mechanism); the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Hereditary spherocytosis, recessive is an R19 double-well emerged from the real proximal-promoter DNA of SPTA1. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis: ↓ DOWN (cited role × mechanism)
healthy branch: ON
lesion: LOF_null
γ (stiffness): 1.2253
barrier: 0.3753
spinodal: 0.5220
s_on / s_off: 1.1069 / -1.1069
fragility: 1.00
corrective polarity: supply
forced direction: raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.3753 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — an interpretation of the model (code output, not a forced biological fact), and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: increasegeometric rank 1.00

Mechanism. supply / restore the positive drive (replace-or-agonise the missing competence)

Applies to. allele-agnostic (downstream/environmental tilt)

favoured when the switch is fragile -- a small drive shift recrosses the fold

Falsifier. If supplying/agonising the SPTA1 alpha-spectrin erythrocyte-membrane-skeleton competence lost (raising the switch drive) does NOT move the DOWN switch toward the healthy branch in a SPTA1-deficient model, the h-restore(supply) lever is refuted for this axis.

gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00

Mechanism. N/A

Applies to. none (honest exclusion)

EXCLUDED: null allele -- no product to stiffen

Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual SPTA1 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)	dir.	status	phase	map
SPTA1 product/function restoration (investigational; no approved repurposing agent mapped) Wichterle 1996 J Clin Invest 98:2300; Perrotta 2008 Lancet 372:1411	increase	investigational	2	◇ in trials

⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
element	grade	basis
R19 switch & cusp geometry (this page)	code output	emerged from measured promoter γ of `SPTA1`; deterministic, 2×sha256 identical
corrective direction	interpretation	code output of the model: the sign follows from the cited lesion role × mechanism (which well the disease occupies); falsifiable (see lever falsifiers); magnitude [O]
mapped agents / leads	[O] open	direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL (read: consistency with established practice, partly by construction, since the corrective sign follows from the cited lesion class) -- the agent is already approved / established standard for this disease, so the direction logic agrees with known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).